Does the Pericardial Closure Reduces Early Right Ventricular Dysfunction After Cardiac Surgery: A Randomized Controlled Trial

September 21, 2026 updated by: Abdelrahman Hamed Ahmed, Assiut University

The right ventricular (RV) function has a major influence on the outcomes of cardiac surgery[1,2]. Also affects the prognosis of patients undergoing heart surgery, where the development of right ventricular failure after surgery is linked to higher rates of morbidity and mortality[3]. Significant clinical consequences result from perioperative impairment of RV function, including increased need for inotropic support, prolonged intensive care unit admission, higher rates of hospital readmission, and a higher risk of in-hospital mortality.[2,4]. Regardless of the use of cardiopulmonary bypass, longitudinal evaluations of RV systolic function, such as tricuspid annular plane systolic excursion (TAPSE) and tricuspid annular systolic velocity (TASV/S'), frequently decrease following elective coronary artery bypass grafting (CABG) [6,7]. Loss of pericardial restriction during pericardiotomy, ischemia from inadequate myocardial protection, and postoperative adhesions that modify RV shape and contraction patterns are theories explaining these perioperative alterations [4,8]. This study employed standard transthoracic echocardiography and speckle-tracking deformation analysis for the assessment of the effect of closing the pericardium on RV function post operatively versus leaving it open.

Study Overview

Study Type

Interventional

Enrollment (Estimated)

90

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Asyut, Egypt
        • Assiut University hospital
        • Contact:
        • Principal Investigator:
          • abdelrahaman hamed Ahmed

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Patients undergoing following surgeries

    • aortic valve replacement (AVR).
    • mitral valve replacement (MVR).
    • combined coronary and/or valvular heart surgeries.
    • coronary artery by-pass graft (CABG).

Exclusion Criteria:

  • • right ventricular dysfunction

    • RV dilatation (RV diameter > 4.5)
    • RV infarction
    • pacemaker stimulation,
    • severe left heart insufficiency (LV-EF ≤ 40%).
    • tricuspid valve insufficiency > 2°.
    • pulmonary valve insufficiency ≥2°,
    • atrial fibrillation/flutter,
    • pulmonary hypertension,
    • state after pulmonary artery embolism.
    • chronic obstructive pulmonary disease > GOLD 2, prior cardiac surgery.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: intervention

closed pericardium

close pericardium by continuous sutures before sternal closure

No Intervention: control

open pericardium

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Tricuspid annular plane systolic excursion (TAPSE)
Time Frame: 3 months

to asses the effect of pericardial closure on the right ventricular function

3 months
Tricuspid annular systolic velocity TASV/S'
Time Frame: 3 month

to asses the effect of pericardial closure on right ventricular function

3 month

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
the postoperative LV function after pericardial closure vs. open pericardium
Time Frame: 3 months

by assessing ejection fraction by early postoperative echocardiography

3 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

December 10, 2026

Primary Completion (Estimated)

December 1, 2029

Study Completion (Estimated)

December 1, 2029

Study Registration Dates

First Submitted

September 11, 2026

First Submitted That Met QC Criteria

September 21, 2026

First Posted (Actual)

September 23, 2026

Study Record Updates

Last Update Posted (Actual)

September 23, 2026

Last Update Submitted That Met QC Criteria

September 21, 2026

Last Verified

September 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • Pericardial Closure postop

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

IPD Plan Description

according to the need of explanation

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe